Hospital de Olhos Sadalla Amin Ghanem specializes in ophthalmology services, providing a range of medical and surgical care options.

Hospital de Olhos Sadalla Amin Ghanem

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Glaukos Corporation

NIDEK CO., LTD. develops and produces medical equipment for eye care and health services. self-described as a provider in the health care sector.

NIDEK CO., LTD.

STAAR designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses.

Metric
Company Name	Hospital de Olhos Sadalla Amin Ghanem	Glaukos Corporation	NIDEK CO., LTD.	STAAR Surgical
Symbol		GKOS
MSH ID	BR:COM:SADALLA	COM:GLAUKOS	COM:NIDEK	COM:STAAR
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Healthcare	Medical - Devices	Medical Devices	Medical Devices
Country	BR	US	JP	US
Stage
Employee Count		907
Website	sadalla.com.br	glaukos.com	nidek.com	staar.com
LinkedIn
Founders

Metric
Market Cap	6.05B
Enterprise Value
Monthly Web Traffic		6.62K
Web Traffic Growth		-0.05
Valuation
Raised Capital

Metric
Revenue		314.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit		239.14M
EBITDA		-82.12M
Operating Income		-128.70M
Net Income		-134.66M
EPS		-2.78
Diluted EPS		-2.78
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.77
Operating Profit Margin		-0.36
EBITDA Margin		-0.26
Net Profit Margin		-0.43
Return on Equity		-0.28
Return on Assets		-0.14
Return on Capital Employed		-0.14

BR:COM:SADALLA

Hospital de Olhos Sadalla Amin Ghanem

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-34.36
P/B Ratio		9.30
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		21.84
EV Multiple		-44.37

Metric
Days Sales Outstanding		47.28
Days Payables Outstanding		51.43
Days Inventory Outstanding		257.02
Operating Cycle		311.72
Cash Conversion Cycle		259.12
Asset Turnover		0.37

Metric
Operating Cash Flow		-57.76M
Free Cash Flow		-78.01M
Cash Flow to Debt		-0.07
Operating Cash Flow/Sales		-0.08
Free Cash Flow Yield		-0.01

Metric
Cash & Equivalents		93.47M
Accounts Receivable		-3.84M
Inventory		41.99M
Goodwill		66.13M
Debt to Capitalization		0.46
Debt to Assets		0.40
Current Ratio		5.95
Quick Ratio		4.68

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.10
R&D to Revenue		0.46
SG&A to Revenue